| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
674,040,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$17.15 - $26.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avantor is a global manufacturer and distributor that provides products and services to customers in the biopharmaceutical, healthcare, education and government and advanced technologies and applied materials industries. Co.'s portfolio includes: Materials and consumables, such as lab products and supplies, formulated silicone materials, customized excipients, and customized single-use assemblies; equipment and instrumentation, such as filtration systems, virus inactivation systems, and incubators; and services and specialty procurement, such as onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
27,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$573,100 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
27,872 |
27,872 |
60,449 |
163,424 |
| Total Sell Value |
$687,456 |
$687,456 |
$1,380,595 |
$4,309,849 |
| Total People Sold |
3 |
3 |
4 |
5 |
| Total Sell Transactions |
4 |
4 |
6 |
15 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sokenu Claudius |
EVP, Chief Legal & Compliance |
• – – |
2023-07-24 |
4 |
A |
$0.00 |
$0 |
D/D |
24,627 |
24,627 |
|
- |
|
| Sahin Kitty |
EVP, Strategy&Corp Development |
• – – |
2023-07-18 |
4 |
D |
$21.01 |
$82,590 |
D/D |
(3,931) |
34,944 |
|
- |
|
| Stubblefield Michael |
President & CEO |
• • – |
2023-05-26 |
4 |
GA |
$0.00 |
$0 |
I/I |
40,000 |
469,500 |
|
- |
|
| Stubblefield Michael |
President & CEO |
• • – |
2023-05-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
40,000 |
1,032,937 |
|
- |
|
| Szlosek Thomas A |
EVP & CFO |
• – – |
2023-05-17 |
4 |
D |
$20.28 |
$471,733 |
D/D |
(23,261) |
77,489 |
|
- |
|
| Eck Steven W |
SVP & Chief Accounting Officer |
• – – |
2023-05-17 |
4 |
D |
$20.28 |
$11,215 |
D/D |
(553) |
21,180 |
|
- |
|
| Stubblefield Michael |
President & CEO |
• • – |
2023-05-17 |
4 |
D |
$20.28 |
$2,153,736 |
D/D |
(106,200) |
1,172,937 |
|
- |
|
| Couturier Christophe |
EVP, AMEA |
• – – |
2023-05-17 |
4 |
D |
$20.28 |
$318,518 |
D/D |
(15,706) |
82,944 |
|
- |
|
| Miller Justin |
EVP & General Counsel |
• – – |
2023-05-17 |
4 |
D |
$20.28 |
$252,466 |
D/D |
(12,449) |
93,336 |
|
- |
|
| Bramwell James |
EVP, Strategic Partners |
• – – |
2023-05-17 |
4 |
D |
$20.28 |
$383,637 |
D/D |
(18,917) |
85,393 |
|
- |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2023-05-17 |
4 |
D |
$20.28 |
$399,171 |
D/D |
(19,683) |
89,032 |
|
- |
|
| Vanderhaegen Frederic |
EVP, Americas and Europe |
• – – |
2023-05-17 |
4 |
D |
$20.28 |
$44,819 |
D/D |
(2,210) |
185,735 |
|
- |
|
| Kang Lan |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,808 |
21,738 |
|
- |
|
| Shaw Christi |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,808 |
36,271 |
|
- |
|
| Murthy Mala |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,808 |
18,632 |
|
- |
|
| Andres Juan |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,808 |
39,903 |
|
- |
|
| Massaro Joseph R |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,808 |
18,461 |
|
- |
|
| Summe Gregory L |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,808 |
32,534 |
|
- |
|
| Carethers John |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,808 |
20,281 |
|
- |
|
| Severino Michael |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,808 |
34,974 |
|
- |
|
| Peacock Jonathan M |
Director |
– • – |
2023-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,808 |
186,147 |
|
- |
|
| Stone Randy Lee |
EVP, Proprietary Products |
• – – |
2023-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
48,332 |
48,332 |
|
- |
|
| Couturier Christophe |
EVP, AMEA |
• – – |
2023-04-11 |
4 |
S |
$21.18 |
$31,728 |
D/D |
(1,498) |
98,650 |
|
1% |
|
| Couturier Christophe |
EVP, AMEA |
• – – |
2023-04-05 |
4 |
D |
$20.82 |
$11,847 |
D/D |
(569) |
100,148 |
|
- |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2023-03-03 |
4 |
AS |
$25.00 |
$97,850 |
D/D |
(3,914) |
108,715 |
|
-17% |
|
534 Records found
|
|
Page 3 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.49 (2.02%) 
